The use of psychedelic drugs to treat resistant PTSD & other disorders – The legal & policy implications
Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. My presentation will briefly introduce delegates to psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. The Multidisciplinary Association for Psychedelic Studies’ (MAPS) MDMA- assisted psychotherapy for treatment-resistant PTSD study with a reported 80% ‘success’ rate (published in the Journal of Psychopharmacology in 2010) will be considered together with completed international Stage 2 trials, planned Stage 3 trials and current UK trials. Full approval from the US Food and Drug Administration and the European Medicines Agency for MDMA-assisted psychotherapy is projected by MAPS to be granted in 2021.MAPS have also received full approval for a medical marijuana drug development study and together with Johns Hopkins University will treat 76 US veterans with treatment-resistant PTSD. The study is funded by a $2.15 million Colorado state grant. Other psychedelic research areas, such as Imperial College London’s recent study of psilocybin for treatment-resistant depression (published in the Lancet in July 2016) will then be brie y touched on as will ongoing studies at Johns Hopkins University and New York University’s into psilocybin for existential stress in terminal cancer patients. I will then look at the legal and policy implications of these areas of research including regulatory approval, drug schedule classification, governmental response and big pharma (dis)interest. The presentation should be well received by EMDR practitioners as these novel (and controversial) areas of research to treat PTSD have promising initial results.
Original Work Citation
Nash, J. (2017, March). The use of psychedelic drugs to treat resistant PTSD & other disorders – The legal & policy implications. Presentation (Matt Kiernan, Chair) at the 15th EMDR Association UK & Ireland Annual Conference & AGM, London, UK
“The use of psychedelic drugs to treat resistant PTSD & other disorders – The legal & policy implications,” Francine Shapiro Library, accessed November 29, 2020, https://emdria.omeka.net/items/show/24305.